Surrozen, Inc./DE Other Comprehensive Income (Loss), Net of Tax
Surrozen, Inc./DE (SRZN) reported Other Comprehensive Income (Loss), Net of Tax of $241.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2025-03-31
- Surrozen, Inc./DE other comprehensive income (loss), net of tax for the quarter ending 2023-09-30 was -$4.00K, a 107.69% decline year-over-year.
- Surrozen, Inc./DE other comprehensive income (loss), net of tax for the quarter ending 2023-06-30 was $55.00K, a 17.02% increase year-over-year.
- Surrozen, Inc./DE other comprehensive income (loss), net of tax for the quarter ending 2023-03-31 was $191.00K.
- Surrozen, Inc./DE other comprehensive income (loss), net of tax for the quarter ending 2022-09-30 was $52.00K.
- Surrozen, Inc./DE other comprehensive income (loss), net of tax for fiscal 2023 was $241.00K.
- Surrozen, Inc./DE other comprehensive income (loss), net of tax for fiscal 2022 was -$122.00K.
- Surrozen, Inc./DE other comprehensive income (loss), net of tax for fiscal 2021 was -$119.00K.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 3 month as first filed | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month |
|---|---|---|---|---|---|
| 2023-12-31 | $241.00K 10-K · filed 2025-03-31 | ||||
| 2023-09-30 | -$4.00K 10-Q · filed 2024-11-06 | $51.00K derived: sum of 2 quarters · filed 2024-11-06 | $242.00K derived: sum of 3 quarters · filed 2024-11-06 | ||
| 2023-06-30 | $55.00K 10-Q · filed 2024-11-06 | $246.00K derived: sum of 2 quarters · filed 2024-11-06 | |||
| 2023-03-31 | $191.00K 10-Q · filed 2024-11-06 | ||||
| 2022-12-31 | -$122.00K 10-K · filed 2024-04-10 | ||||
| 2022-09-30 | $52.00K 10-Q · filed 2023-11-08 | $99.00K derived: sum of 2 quarters · filed 2023-11-08 | -$211.00K derived: sum of 3 quarters · filed 2023-11-08 | ||
| 2022-06-30 | $47.00K 10-Q · filed 2023-11-08 | -$47.00K 10-Q · filed 2022-08-11 | -$263.00K derived: sum of 2 quarters · filed 2023-11-08 | ||
| 2022-03-31 | -$310.00K 10-Q · filed 2023-11-08 | ||||
| 2021-12-31 | -$119.00K 10-K · filed 2023-03-31 | ||||
| 2021-09-30 | -$16.00K 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |